In Rare Move, FDA Panel Gives Support to Controversial ALS Drug in Second Review
THURSDAY, Sept. 8, 2022 (HealthDay News) — In a rare second review, a U.S. Food and Drug Administration panel on Wednesday recommended approval for an experimental drug for amyotrophic lateral sclerosis (ALS). The FDA is not obligated to follow its a…
Learn MoreTexas Judge Says ACA Cannot Require Coverage for PrEP
THURSDAY, Sept. 8, 2022 (HealthDay News) — Hundreds of thousands of Americans take medications intended to prevent infection with HIV, but a federal judge in Texas ruled Wednesday that a provision in the Affordable Care Act (ACA) that requires free c…
Learn MoreReduction in Swollen, Tender Joints Greater With Litifilimab in Lupus
THURSDAY, Sept. 8, 2022 (HealthDay News) — Patients with systemic lupus erythematosus (SLE) receiving litifilimab, a humanized monoclonal antibody that binds to blood dendritic cell antigen 2, versus placebo have a greater reduction in the number of …
Learn MoreFDA Panel Skeptical of Controversial ALS Drug Ahead of Vote
TUESDAY, Sept. 6, 2022 (HealthDay News) — A U.S. Food and Drug Administration panel will once again consider approval for an experimental drug for amyotrophic lateral sclerosis (ALS), a rare second review for a disease that has no cure.
The same pane…
Bronchodilator Does Not Improve Respiratory Symptoms for Tobacco-Exposed
TUESDAY, Sept. 6, 2022 (HealthDay News) — For symptomatic, tobacco-exposed persons with preserved lung function, inhaled dual bronchodilator therapy does not reduce respiratory symptoms, according to a study published online Sept. 4 in the New Englan…
Learn MoreSGLT2 Inhibitors Benefit Broad Range of Heart Failure Patients
FRIDAY, Sept. 2, 2022 (HealthDay News) — Sodium-glucose cotransporter 2 (SGLT2) inhibitors cut the risk for cardiovascular death and hospitalization for heart failure in patients with heart failure, regardless of ejection fraction, according to a s…
Learn MoreDolutegravir Compared With Other Regimens for HIV in Pregnancy
THURSDAY, Sept. 1, 2022 (HealthDay News) — HIV-1 viral suppression at delivery is less frequent with atazanavir-ritonavir and raltegravir than dolutegravir during pregnancy, according to a study published in the Sept. 1 issue of the New England Jou…
Learn MoreVamorolone Effective, Safe for Boys With Duchenne Muscular Dystrophy
THURSDAY, Sept. 1, 2022 (HealthDay News) — For boys with Duchenne muscular dystrophy (DMD), vamorolone, a structurally unique dissociative steroidal anti-inflammatory drug, is effective and safe over a 24-week period, according to a study published…
Learn MoreUblituximab Bests Teriflunomide in Relapsing Multiple Sclerosis
WEDNESDAY, Aug. 31, 2022 (HealthDay News) — Patients with relapsing multiple sclerosis receiving ublituximab have lower annualized relapse rates and fewer brain lesions on magnetic resonance imaging than those receiving teriflunomide, according to a …
Learn MoreSARS-CoV-2 mAbs Continued to Be Used After FDA Deauthorization
TUESDAY, Aug. 30, 2022 (HealthDay News) — More than 158,000 doses of two anti-severe acute respiratory syndrome coronavirus 2 monoclonal antibodies (mAbs), bamlanivimab-etesevimab and casirivimab-imdevimab, were administered in early 2022, despite de…
Learn More